

95TH ADVISORY FORUM  
WARSAW, 06-07 MARCH 2025

# THE EU SUMMARY REPORT ON ANTIMICROBIAL RESISTANCE (AMR) IN 2022- 2023

Valentina Rizzi/ BIOHAW unit

# REPORTING AMR IN THE EU

## ❑ Outcomes of the monitoring

- Occurrence of AMR
- Combined resistance to **Critically Important Antimicrobials (CIAs)**
- **Key Outcome Indicators** of AMR:
  - **Complete Susceptibility** in indicator *E. coli*
  - **Prevalence of ESBL/AmpC-** producing *E. coli*
- **Temporal trends**

Inclusion of human, animal and food data allows:

- **One Health approach,**
- **Integrated analyses** across humans and food/animals,
- Comparison of resistance/ particular resistance profiles.

➡ In the animal/ food sector, AMR **monitoring** is performed on a **biennial basis** and the **sampling** in a **rotating basis**

} ➡ Good compromise between scientific needs and MSs capacities



# EUSR AMR 2022-2023 – MAIN FINDINGS

- Resistance to **commonly used antimicrobials** in veterinary medicine (ampicillin, tetracyclines and sulfonamides):
  - remains high for ***Salmonella*** and ***Campylobacter*** isolates from humans and food-producing-animals (except for *Salmonella* in laying hens).
  - is also frequently detected in ***E. coli*** isolates from food-producing animals.



# EUSR AMR 2022-2023 – MAIN FINDINGS

- The **high/ extremely high** resistance to **ciprofloxacin**, a critically important antimicrobial for human treatment, is of concern. It has been observed in:
  - ***C. jejuni*** and ***C. coli*** from humans and food-producing animals
  - ***Salmonella*** from humans and poultry
  - ***E. coli*** from poultry
- Resistance to **other critically important antimicrobials** for human medicine is **uncommon** (E.g. 3<sup>rd</sup> generation cephalosporins in *Salmonella* and *E. coli*, macrolides in *Campylobacter*).



# EUSR AMR 2022-2023 – MAIN FINDINGS

- **Carbapenem resistance** remains rare but concerning.

***Salmonella spp.***: Carbapenemase-producing (CP) isolates were found in humans (5 in 2022 and 6 in 2023) but **not** in food-producing animals.

***E. coli***: CP-isolates were detected in food-producing animals (pigs, cattle under 1 year of age, poultry and meat thereof) at **very low level**.

**BUT**

Presence of carbapenemase-producing bacteria in several countries/ several animal species and with several genes...

... highlights the need for continued monitoring, and further epidemiological investigations.



# EUSR AMR 2022-2023 – MAIN FINDINGS

## KEY OUTCOME INDICATOR COMPLETE SUSCEPTIBILITY IN INDICATOR *E. COLI* (KOI CS)



Marked variations  
among countries



Statistically  
significant  
**increasing trends in  
44.4% of the  
reporting countries  
(12 of 27)**

## KEY OUTCOME INDICATOR PREVALENCE OF ESBL- AND/OR AMPC-PRODUCING *E. COLI* (KOI ESBL)



Marked variations  
among countries



Statistically  
significant  
**decreasing trends in  
70% of the reporting  
countries (21 of 30)**

# BIOHAZ SELF-TASK

## CARBAPENEMASE-PRODUCING ENTEROBACTERALES IN FOOD CHAIN

**Time:** 3 years, June 2024- June 2027

### Outputs:

- **BIOHAZ scientific opinion** on the **state of the art** (including results to a survey to MSs)
- **Monopole Framework Partnership agreement (FPA)** with EURL/NRLs-AR Network, **external reports**
- **BIOHAZ scientific opinion** evaluating the **results of the project**, **advice** to risk managers



**FPA “data generation on CPs in food-producing animals”**  
**Contract: 2.5 years (mid 2024-end 2026),**  
**Budget 1.5 mill Co-funding (20%).**

**Contractor (coordinator + MSs):**  
**EURL-AR/NRLs-AR Network labs, Art. 36**  
**<https://www.eurl-ar.eu/participants.aspx>**



# DIFFICULTIES ENCOUNTERED BY MS IN DATA PROVISION

1. Resources constraints (related to limited availability of budget for data analyses)
2. Variability in the analytical capacity (about technologies and competencies) between MSs, e.g. in relation to the use of the new technologies such as WGS
3. Turnover of people involved in data reporting (data providers) and of AMR Network Members
4. Accuracy and completeness of the AMR data:
  - a. Data fragmentation due to different data sources and different actors involved at country level → Coordination within the country
  - b. Manual manipulation of the data prone to errors
5. Timelines for data validation/ corrections





# COLLABORATION WITH MS

1. Harmonised monitoring and reporting system (Revision of the guidelines and technical specifications)
2. Technical and scientific support and assistance (training activities for data reporting)
3. Knowledge transfer (during the annual AMR network meetings, and throughout the year via web communication tools)
4. Grants and procurements:
  - a. For automatisation of data extraction and data transmission
  - b. For increasing the data quality
  - c. For designing the reporting tools and reporting system



# STAY CONNECTED

## SUBSCRIBE TO

[efsa.europa.eu/en/news/newsletters](https://efsa.europa.eu/en/news/newsletters)

[efsa.europa.eu/en/rss](https://efsa.europa.eu/en/rss)

[Careers.efsa.europa.eu](https://careers.efsa.europa.eu) – job alerts



## FOLLOW US ON TWITTER

[@efsa\\_eu](https://twitter.com/efsa_eu)

[@methods\\_efsa](https://twitter.com/methods_efsa)

[@plants\\_efsa](https://twitter.com/plants_efsa)

[@animals\\_efsa](https://twitter.com/animals_efsa)



## FOLLOW US ON INSTAGRAM

[@one\\_healthenv\\_eu](https://www.instagram.com/one_healthenv_eu)



## LISTEN TO OUR PODCAST

Science on the Menu – Spotify, Apple Podcast and YouTube



## FOLLOW US ON LINKEDIN

[Linkedin.com/company/efsa](https://linkedin.com/company/efsa)



## CONTACT US

[efsa.europe.eu/en/contact/askefsa](https://efsa.europe.eu/en/contact/askefsa)

